CDK4 as a phytochemical based anticancer drug target

Ashraf, M. Arif; Sayed, Shomoita; Bello, Martiniano; Hussain, Nazmul; Chando, Rony Kumer; Alam, Saruar; Hasan, Md. Kamrul

doi:10.1016/j.imu.2021.100826

Cited by 4 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The levels of CDKs are regulated by cyclin-dependent kinase inhibitors (CKIs), which maintain the level of CDKs [ 223 ]. Various phytochemicals, such as mangiferin [ 224 ], naringenin [ 225 ], berberine [ 226 ], fisetin [ 227 ], etc., have demonstrated inhibitory potentials for the progression of the cell cycle. Ferulic acid from Allium cepa has been studied to elevate the expression of genes associated with the association of centrosomes and arrest the cell cycle at the synthesis (S) phase, which results in the inhibition of colon cancer Caco-2 cells [ 228 ].…”

Section: Mechanism Of Action Of Phytochemicalsmentioning

confidence: 99%

Insight into the Biological Roles and Mechanisms of Phytochemicals in Different Types of Cancer: Targeting Cancer Therapeutics

et al. 2023

View full text Add to dashboard Cite

Cancer is a hard-to-treat disease with a high reoccurrence rate that affects health and lives globally. The condition has a high occurrence rate and is the second leading cause of mortality after cardiovascular disorders. Increased research and more profound knowledge of the mechanisms contributing to the disease’s onset and progression have led to drug discovery and development. Various drugs are on the market against cancer; however, the drugs face challenges of chemoresistance. The other major problem is the side effects of these drugs. Therefore, using complementary and additional medicines from natural sources is the best strategy to overcome these issues. The naturally occurring phytochemicals are a vast source of novel drugs against various ailments. The modes of action by which phytochemicals show their anti-cancer effects can be the induction of apoptosis, the onset of cell cycle arrest, kinase inhibition, and the blocking of carcinogens. This review aims to describe different phytochemicals, their classification, the role of phytochemicals as anti-cancer agents, the mode of action of phytochemicals, and their role in various types of cancer.

show abstract

Section: Mechanism Of Action Of Phytochemicalsmentioning

confidence: 99%

Insight into the Biological Roles and Mechanisms of Phytochemicals in Different Types of Cancer: Targeting Cancer Therapeutics

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Thus, based on the outcome, they predict that 101 can act as a potent ATP competitive inhibitor (Reddy et al, 2022). Ashraf et al (2022) identified mangiferin (106) (Fig. 22), a xanthonoid extracted from the bark and leaves of the mango tree, as a potential anticancer drug that targets CDK4.…”

Section: Cyclin-dependent Kinase 4 (Cdk4)mentioning

confidence: 99%

A comprehensive analysis of the role of molecular docking in the development of anticancer agents against the cell cycle CDK enzyme

SOLANKI¹,

RANA²,

Jha³

et al. 2023

Biocell

View full text Add to dashboard Cite

Cancer is considered one of the most lethal diseases responsible for causing deaths worldwide. Although there have been many breakthroughs in anticancer development, cancer remains the major cause of death globally. In this regard, targeting cancer-causing enzymes is one of the efficient therapeutic strategies. Biological functions like cell cycle, transcription, metabolism, apoptosis, and other depend primarily on cyclin-dependent kinases (CDKs). These enzymes help in the replication of DNA in the normal cell cycle process, and deregulation in the functioning of any CDK can cause abnormal cell growth, which leads to cancer. This review is focused on anticancer drug discovery against cell cycle CDK enzyme using an in silico technique, i.e., molecular docking studies. Molecular docking helps in deciphering the key interactions formed within the inhibitor and the respective enzyme. This concise study provides an overview of the most current in silico research advancements made in the field of anticancer drug discovery. The findings presented in the current review article can help in understanding the nature of inhibitor-target interactions and provide information on the structural and molecular prerequisites for the inhibition of cell cycle CDKs.

show abstract

“…Several plant-derived substances, including Vinblastine [ 30 ], Taxol [ 31 ], and Topotecan [ 32 ], etc., are used as cancer therapeutics in clinical research. Because of recent advances in genomics and proteomics, determining the target prospective phytocompounds has exhibited effective anticancer potential in several clinical cancer research studies [ 33 , 34 ]. However, the discovery of new anticancer drugs has become an urgent requirement in modern times because of raising the drug’s resistance properties to cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Study of MDM2 as Prognostic Biomarker in Brain-LGG Cancer and Bioactive Phytochemicals Inhibit the p53-MDM2 Pathway: A Computational Drug Development Approach

Biswas¹,

Bibi

Yousafi

et al. 2023

Molecules

View full text Add to dashboard Cite

An evaluation of the expression and predictive significance of the MDM2 gene in brain lower-grade glioma (LGG) cancer was carried out using onco-informatics pipelines. Several transcriptome servers were used to measure the differential expression of the targeted MDM2 gene and search mutations and copy number variations. GENT2, Gene Expression Profiling Interactive Analysis, Onco-Lnc, and PrognoScan were used to figure out the survival rate of LGG cancer patients. The protein–protein interaction networks between MDM2 gene and its co-expressed genes were constructed by Gene-MANIA tool. Identified bioactive phytochemicals were evaluated through molecular docking using Schrödinger Suite Software, with the MDM2 (PDB ID: 1RV1) target. Protein–ligand interactions were observed with key residues of the macromolecular target. A molecular dynamics simulation of the novel bioactive compounds with the targeted protein was performed. Phytochemicals targeting MDM2 protein, such as Taxifolin and (-)-Epicatechin, have been shown with more highly stable results as compared to the control drug, and hence, concluded that phytochemicals with bioactive potential might be alternative therapeutic options for the management of LGG patients. Our once informatics-based designed pipeline has indicated that the MDM2 gene may have been a predictive biomarker for LGG cancer and selected phytochemicals possessed outstanding interaction results within the macromolecular target’s active site after utilizing in silico approaches. In vitro and in vivo experiments are recommended to confirm these outcomes.

show abstract

CDK4 as a phytochemical based anticancer drug target

Cited by 4 publications

References 48 publications

Insight into the Biological Roles and Mechanisms of Phytochemicals in Different Types of Cancer: Targeting Cancer Therapeutics

Insight into the Biological Roles and Mechanisms of Phytochemicals in Different Types of Cancer: Targeting Cancer Therapeutics

A comprehensive analysis of the role of molecular docking in the development of anticancer agents against the cell cycle CDK enzyme

Study of MDM2 as Prognostic Biomarker in Brain-LGG Cancer and Bioactive Phytochemicals Inhibit the p53-MDM2 Pathway: A Computational Drug Development Approach

Contact Info

Product

Resources

About